Abstract

The University of Southern California (USC) and its Comprehensive Cancer Center have been members of the Southwest Oncology Group since 1987, having joined after assessment of institutional strengths and commitment to fully integrate clinical activities of the Los Angeles County (LAC)+ USC Hospital into research opportunities. In the ensuing 5 years, Dr. Franco Muggia has obtained broad institutional support for multidisciplinary involvement in Southwest Oncology Group programs, with increasing capabilities to involve minority populations in LAC + USC into such trials. Strengths include: 1) an experienced and dedicated Clinical Investigations Support Office providing optimal data entry and retrieval, quality control, as well as supervision of the fledgling community Cooperative Group Outreach Programs (CGOPs) in the LA area, 2) Cancer Center programs with depth in clinical trials and basic research and 3) specific contributions in breast cancer adjuvant trials, in gastrointestinal cancer multimodality research, hematologic and AIDS-related neoplasia, gynecologic cancer locoregional therapy and drug pharmacology, biological therapy of melanoma, systemic therapy in pulmonary cancer, and clinico-pathologic study of bone and soft tissue sarcomas. Future efforts will concentrate on consolidating additional multidisciplinary participation services for ensuring timely minority patient entry, and cross-fertilization of basic and clinical research.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA058882-02
Application #
2099513
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1993-02-01
Project End
1997-12-31
Budget Start
1994-01-12
Budget End
1994-12-31
Support Year
2
Fiscal Year
1994
Total Cost
Indirect Cost

  Institution

Name
University of Southern California
Department
Radiation-Diagnostic/Oncology
Type
Schools of Medicine
DUNS #
041544081
City
Los Angeles
State
CA
Country
United States
Zip Code
90089

  Publications

Sonpavde, Guru; Pond, Gregory R; Plets, Melissa et al. (2017) Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated on SWOG Study S0421. Clin Genitourin Cancer 15:635-641
Lara Jr, Primo N; Moon, James; Redman, Mary W et al. (2016) Disease Control Rate at 8 Weeks Predicts Subsequent Survival in Platinum-Treated Extensive Stage Small-Cell Lung Cancer: Results From the Southwest Oncology Group (SWOG) Database. Clin Lung Cancer 17:113-8.e1-2
Ji, Yongli; Rankin, Cathryn; Grunberg, Steven et al. (2015) Double-Blind Phase III Randomized Trial of the Antiprogestin Agent Mifepristone in the Treatment of Unresectable Meningioma: SWOG S9005. J Clin Oncol 33:4093-8
Bohanes, Pierre; Rankin, Cathryn J; Blanke, Charles D et al. (2015) Pharmacogenetic Analysis of INT 0144 Trial: Association of Polymorphisms with Survival and Toxicity in Rectal Cancer Patients Treated with 5-FU and Radiation. Clin Cancer Res 21:1583-90
Lara Jr, Primo N; Moon, James; Redman, Mary W et al. (2015) Relevance of platinum-sensitivity status in relapsed/refractory extensive-stage small-cell lung cancer in the modern era: a patient-level analysis of southwest oncology group trials. J Thorac Oncol 10:110-5
Goldkorn, Amir; Ely, Benjamin; Tangen, Catherine M et al. (2015) Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer 136:1856-62
Othus, Megan; Appelbaum, Frederick R; Petersdorf, Stephen H et al. (2015) Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy. Biol Blood Marrow Transplant 21:559-64
Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64
Yao, S; Sucheston, L E; Zhao, H et al. (2014) Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. Pharmacogenomics J 14:241-7
Smerage, Jeffrey B; Barlow, William E; Hortobagyi, Gabriel N et al. (2014) Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol 32:3483-9

Showing the most recent 10 out of 134 publications